June 07th, 2025

Several high-profile companies are set to announce quarterly financial results on Wednesday, June 11, including: Oracle Corporation (NYSE: ORCL), a global leader in database software and cloud infrastructure, will report its fiscal 2025 fourth-qua. Read more

March 09th, 2025

Several notable companies are set to report earnings on Monday, March 10, including: Global technology giant Oracle Corporation (NYSE: ORCL) will announce its third-quarter fiscal 2025 financial results following the market close. Analysts expect . Read more

December 10th, 2023

On Monday, December 11, several companies are poised to unveil their financial results, including: Oracle Corporation (NYSE: ORCL), a global technology giant, is set to disclose its second-quarter fiscal year 2024 results after the market closes.&. Read more

October 09th, 2023

HC Wainwright & Co. has initiated coverage on Scilex Holding Company (Nasdaq: SCLX), a pharmaceutical company, with a Buy rating and a price target of $12. Closing at $1.57 on Friday, this price target suggests a substantial potential upside of $1. Read more

September 11th, 2023

Oracle Corporation (NYSE: ORCL), a global technology company, reported first-quarter fiscal 2024 earnings of $1.19 per share, surpassing the consensus EPS estimate of $1.15. However, the company's quarterly revenues of $12.45 billion fell slightly be. Read more

September 09th, 2023

Some of the companies expected to report financial results on Monday, September 11, include: Oracle Corporation (NYSE: ORCL), a global tech giant known for its database software and cloud computing solutions, is set to release its first-quarter fi. Read more

June 12th, 2023

iBio, Inc. (NYSE American: IBIO) has partnered with the National Institute of Allergy and Infectious Diseases (NIAID) to explore the potential of the company's AI-driven epitope steering platform in developing a vaccine for Lassa fever, a severe and . Read more

June 09th, 2023

23andMe Holding Co. (Nasdaq: ME), a leading genetic testing and personal genomics company, has disclosed in a regulatory filing with the SEC a reduction in force involving around 75 employees, representing approximately 9% of its workforce.  . Read more

June 07th, 2023

FibroGen, Inc. (Nasdaq: FGEN) announced the topline data from the Phase 3 LELANTOS-1 trial, evaluating pamrevlumab as a treatment for non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids.  Unfortunately. Read more